PT  - JOURNAL ARTICLE
AU  - Derlin, Thorsten
AU  - Kleine-Döpke, Dennis
AU  - Neubert, Lavinia
AU  - Ross, Tobias L.
AU  - Ringe, Bastian P.
AU  - Schmelzle, Moritz
AU  - Bengel, Frank M.
TI  - Initial Experience with Dual-Time-Point [<sup>18</sup>F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism
AID  - 10.2967/jnumed.124.269387
DP  - 2025 Apr 24
TA  - Journal of Nuclear Medicine
PG  - jnumed.124.269387
4099  - http://jnm.snmjournals.org/content/early/2025/04/24/jnumed.124.269387.short
4100  - http://jnm.snmjournals.org/content/early/2025/04/24/jnumed.124.269387.full
AB  - We aimed to evaluate the feasibility of [18F]flurpiridaz PET/CT for localization of parathyroid adenomas in patients with primary hyperparathyroidism (pHPT). Methods: Data for 11 patients with pHPT undergoing dual-time-point [18F]flurpiridaz PET/CT for localization of hyperfunctioning parathyroid glands were retrospectively analyzed. PET/CT findings were compared with results of other imaging tests, laboratory parameters, intraoperative findings, and final histology, serving as the reference standard. Results: [18F]flurpiridaz PET/CT identified parathyroid adenomas in 10 (91%) of the 11 patients studied. Parathyroid adenomas were exclusively visualized in early PET images. Uptake in adenomas declined over time (SUVmax, −65% ± 17%; P = 0.002), as did uptake in background thyroid tissue (−56% ± 16%; P = 0.002). Conclusion: [18F]flurpiridaz PET images after administration had high detection efficacy in pHPT. This work provides a rationale for larger prospective studies to evaluate the use of [18F]flurpiridaz PET/CT for localization of hyperfunctioning parathyroid glands in comparison with other imaging tests.